Lisa Heine
Director/Board Member bei SURMODICS, INC.
Vermögen: 394 711 $ am 31.03.2024
Profil
Lisa Wipperman Heine is the founder of Dearca Strategic Solutions LLC, which was founded in 2014.
She is currently an Independent Director at Surmodics, Inc., a Director at Gradient Denervation Technologies SAS, and an Independent Director at Nyra Medical, Inc. Ms. Heine's former positions include President & Chief Executive Officer at Precardia, Inc., Independent Director at Natus Medical, Inc., Independent Director at Miromatrix Medical, Inc., and Non-Executive Director at TrivarX Ltd.
She also held positions at Mitralign, Inc., Vascular Therapies, Inc., and Covidien Unlimited Co. Ms. Heine received an undergraduate degree from St. Olaf College and a graduate degree from the University of Manitoba.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SURMODICS, INC.
0,09% | 08.02.2024 | 13 453 ( 0,09% ) | 394 711 $ | 31.03.2024 |
Aktive Positionen von Lisa Heine
| Unternehmen | Position | Beginn |
|---|---|---|
| SURMODICS, INC. | Director/Board Member | 12.04.2017 |
Gradient Denervation Technologies SAS
 Gradient Denervation Technologies SAS Miscellaneous Commercial ServicesCommercial Services Gradient Denervation Technologies SAS engages in research and development in other physical and natural sciences. The company is headquartered in Paris, France. | Director/Board Member | 01.01.2022 |
Nyra Medical, Inc.
 Nyra Medical, Inc. Medical SpecialtiesHealth Technology The American company is focused on developing the Carlen technology, a transcatheter technology for the treatment of mitral regurgitation. The technology preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options. Nyra Medical is also developing a novel transcatheter mitral and tricuspid valve repair technology called the Cardiac Leaflet Enhancer (Carlen), which enables repair of leaky heart valves without the need for open heart surgery. Lori B. Chmura has been the CEO of the company since 2023. | Director/Board Member | - |
Ehemalige bekannte Positionen von Lisa Heine
| Unternehmen | Position | Ende |
|---|---|---|
| MIROMATRIX MEDICAL INC. | Director/Board Member | 11.12.2023 |
| NATUS MEDICAL INCORPORATED | Director/Board Member | 21.07.2022 |
Precardia, Inc.
 Precardia, Inc. Medical SpecialtiesHealth Technology Precardia, Inc. is an American medical technology company that aims to improve the quality of life for patients suffering from acute decompensated heart failure (ADHF). The company's proprietary balloon catheter and pump controller technology is designed to address ADHF through cardio-renal volume unloading via intermittent superior vena cava (SVC) occlusion. Precardia's system is an investigational device and is limited by federal law to investigational use. The company was founded and incubated by MD Start and is headquartered in the USA. The company was founded by Tim Lenihan. Precardia was acquired by ABIOMED, Inc. on June 01, 2021 for $82.80 million. | Chief Executive Officer | 01.05.2021 |
| TRIVARX LIMITED | Director/Board Member | 22.11.2019 |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Chief Operating Officer | 01.11.2018 |
Ausbildung von Lisa Heine
| St. Olaf College | Undergraduate Degree |
| University of Manitoba | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SURMODICS, INC. | Health Technology |
| MIROMATRIX MEDICAL INC. | Health Technology |
| TRIVARX LIMITED | Technology Services |
| Private Unternehmen | 9 |
|---|---|
ABIOMED, Inc.
 ABIOMED, Inc. Medical SpecialtiesHealth Technology ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA. | Health Technology |
Natus Medical, Inc.
 Natus Medical, Inc. Medical SpecialtiesHealth Technology Natus Medical, Inc. engages in providing healthcare solutions. It also focuses on the diagnosis and treatment of central nervous and sensory system disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William Jr. New, Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Middleton, WI. | Health Technology |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
Vascular Therapies, Inc.
 Vascular Therapies, Inc. Medical SpecialtiesHealth Technology Vascular Therapies, Inc. operates as a biopharmaceutical firm that develops and commercialize treatments of patients requiring an AV fistula for dialysis. It provides plan on the hemodialysis vascular access indication. The company was founded by Sriram Iyer in 2001 and is headquartered in Cresskill, NJ. | Health Technology |
Covidien Unlimited Co.
 Covidien Unlimited Co. Medical SpecialtiesHealth Technology Covidien Unlimited Co. engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings. It operates through Medical Devices and U.S. Medical Supplies segments. The Medical Devices segment involves in the distribution of surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. The U.S. Medical Supplies segment includes marketing of nursing care, medical surgical, SharpSafety brand, and original equipment manufacturer (OEM) products. The company was founded in 1967 and is headquartered in Dublin, Ireland. | Health Technology |
| Dearca Strategic Solutions LLC | |
Precardia, Inc.
Precardia, Inc. Medical SpecialtiesHealth Technology Precardia, Inc. is an American medical technology company that aims to improve the quality of life for patients suffering from acute decompensated heart failure (ADHF). The company's proprietary balloon catheter and pump controller technology is designed to address ADHF through cardio-renal volume unloading via intermittent superior vena cava (SVC) occlusion. Precardia's system is an investigational device and is limited by federal law to investigational use. The company was founded and incubated by MD Start and is headquartered in the USA. The company was founded by Tim Lenihan. Precardia was acquired by ABIOMED, Inc. on June 01, 2021 for $82.80 million. | Health Technology |
Gradient Denervation Technologies SAS
Gradient Denervation Technologies SAS Miscellaneous Commercial ServicesCommercial Services Gradient Denervation Technologies SAS engages in research and development in other physical and natural sciences. The company is headquartered in Paris, France. | Commercial Services |
Nyra Medical, Inc.
Nyra Medical, Inc. Medical SpecialtiesHealth Technology The American company is focused on developing the Carlen technology, a transcatheter technology for the treatment of mitral regurgitation. The technology preserves the physiological valve geometry while restoring its function, eliminates the risk of stenosis, and offers the benefit of preserving a full range of transcatheter and surgical treatments as future options. Nyra Medical is also developing a novel transcatheter mitral and tricuspid valve repair technology called the Cardiac Leaflet Enhancer (Carlen), which enables repair of leaky heart valves without the need for open heart surgery. Lori B. Chmura has been the CEO of the company since 2023. | Health Technology |
